Ventyx Biosciences Inc（VTYX）の財務VTYXVentyx Biosciences Inc

Evaluating the bottom line, Ventyx Biosciences, Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -45.35%, provide a clear picture of how effectively VTYX converts its operational activities into shareholder value.

In the context of the broader market, VTYX competes directly with industry leaders such as CMPX and DBVT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, VTYX's gross margin of N/A stands against CMPX's N/A and DBVT's 100.00%. Such benchmarking helps identify whether Ventyx Biosciences, Inc is trading at a premium or discount relative to its financial performance.

In Q3 2025, revenue remained at $0 with no growth. Net income dropped by 35.24% YoY to -$22.83 million, and EPS declined by 36% YoY to -$0.32. Gross margin remained at 0%. The financials indicate poor performance and no growth trends.